Escitalopram: Apo-Escitalopram is the new funded brand
Escitalopram is used to treat depression, social anxiety, generalised anxiety and obsessive compulsive disorder.
Earlier this year, due to some supply issues, we had to fund several different brands of escitalopram. We have now secured funding of the Apo-Escitalopram brand.
What is changing?
The funded brand of escitalopram will now be Apo-Escitalopram
Your new brand is available from 1 October 2017
- From 1 October 2017 Apo-Escitalopram will be fully funded and available for patients
- From 1 March 2018 only Apo-Escitalopram will be fully funded. Accord, Air Flow and Loxolate brands will no longer be funded.
Apo-Escitalopram works the same as the other brands
- Apo-Escitalopram will work the same way as other brands of escitalopram. Apo-Escitalopram has the same active ingredient as other brands and is delivered to the body in the same way. This means it will have the same effect as other brands.
- Apo-Escitalopram has been thoroughly evaluated by Medsafe to ensure it is safe and works the same as other brands.
Find out more
If you have any questions or concerns, talk to your doctor, nurse or pharmacist.
You can also get more information from us at firstname.lastname@example.org or 0800 66 00 50.
Last updated: 1 September 2017